Literature DB >> 25286762

MicroRNA-495 mimics delivery inhibits lung tumor progression.

Cheng Ai1, Rujian Jiang, Li Fu, Youdong Chen.   

Abstract

MicroRNAs (miRNAs) can function as tumor suppressors and might provide an efficient strategy for annihilating cancer. Specific miRNAs can be reintroduced into tumor cells to elicit the tumor suppressor activities. We show that systemically delivered, synthetic miRNA mimics in complex with a novel neutral lipid emulsion are preferentially targeted to lung tumors and show therapeutic benefit in mouse models of lung cancer. The delivery was demonstrated using mimics of the tumor suppressor microRNA-495 which is found downregulated in most lung cancer. Systemic treatment of a Kras-activated autochthonous mouse model of non-small cell lung cancer (NSCLC) led to a significant decrease in tumor burden. Specifically, mice treated with microRNA-495 displayed a large reduction in tumor area compared to mice treated with a miRNA control. These findings provide direct evidence that systematically delivered synthetic miRNA mimics to the mammalian lung can inhibit tumor proliferation and support the promise of miRNAs as a targeted therapy for lung cancer in future.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25286762     DOI: 10.1007/s13277-014-2687-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

2.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.

Authors:  Jason F Wiggins; Lynnsie Ruffino; Kevin Kelnar; Michael Omotola; Lubna Patrawala; David Brown; Andreas G Bader
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

3.  Secreted monocytic miR-150 enhances targeted endothelial cell migration.

Authors:  Yujing Zhang; Danqing Liu; Xi Chen; Jing Li; Limin Li; Zhen Bian; Fei Sun; Jiuwei Lu; Yuan Yin; Xing Cai; Qi Sun; Kehui Wang; Yi Ba; Qiang Wang; Dongjin Wang; Junwei Yang; Pingsheng Liu; Tao Xu; Qiao Yan; Junfeng Zhang; Ke Zen; Chen-Yu Zhang
Journal:  Mol Cell       Date:  2010-07-09       Impact factor: 17.970

Review 4.  The promise of microRNA replacement therapy.

Authors:  Andreas G Bader; David Brown; Matthew Winkler
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

5.  Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues.

Authors:  Junming Guo; Ying Miao; Bingxiu Xiao; Rong Huan; Zhen Jiang; Dan Meng; Yanjun Wang
Journal:  J Gastroenterol Hepatol       Date:  2008-11-03       Impact factor: 4.029

6.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Authors:  Charles N Landen; Arturo Chavez-Reyes; Corazon Bucana; Rosemarie Schmandt; Michael T Deavers; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

7.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Authors:  Aurora Esquela-Kerscher; Phong Trang; Jason F Wiggins; Lubna Patrawala; Angie Cheng; Lance Ford; Joanne B Weidhaas; David Brown; Andreas G Bader; Frank J Slack
Journal:  Cell Cycle       Date:  2008-03-03       Impact factor: 4.534

8.  Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family.

Authors:  Kazuo Motoyama; Hiroshi Inoue; Yoshito Nakamura; Hiroyuki Uetake; Kenichi Sugihara; Masaki Mori
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

9.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

10.  MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6.

Authors:  Shu-Mei Chen; Hua-Chien Chen; Shu-Jen Chen; Chiung-Yin Huang; Pin-Yuan Chen; Tai-Wei Erich Wu; Ly-Ying Feng; Hong-Chieh Tsai; Tai-Ngar Lui; Chuen Hsueh; Kuo-Chen Wei
Journal:  World J Surg Oncol       Date:  2013-04-17       Impact factor: 2.754

View more
  7 in total

1.  miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1.

Authors:  Leiguang Ye; Hui Wang; Baogang Liu
Journal:  Tumour Biol       Date:  2015-08-16

2.  MicroRNA-665 suppressed the invasion and metastasis of osteosarcoma by directly inhibiting RAB23.

Authors:  Chenhui Dong; Quanyin Du; Zimin Wang; Yu Wang; Siyu Wu; Aimin Wang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  Leukocyte response is regulated by microRNA let7i in patients with acute ischemic stroke.

Authors:  Glen C Jickling; Bradley P Ander; Natasha Shroff; Miles Orantia; Boryana Stamova; Cheryl Dykstra-Aiello; Heather Hull; Xinhua Zhan; DaZhi Liu; Frank R Sharp
Journal:  Neurology       Date:  2016-10-26       Impact factor: 9.910

Review 4.  Targeting MicroRNAs in Cancer Gene Therapy.

Authors:  Weidan Ji; Bin Sun; Changqing Su
Journal:  Genes (Basel)       Date:  2017-01-09       Impact factor: 4.096

5.  miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.

Authors:  Zhenyou Zou; Ruyi Zou; Dan Zong; Yonghong Shi; Jinyao Chen; Jie Huang; Jiahui Zhu; Liguan Chen; Xiaoyan Bao; Yuan Liu; Weihao Liu; Wenhui Huang; Jingsang Hu; Zhi Chen; Xiaojie Lao; Chaoqun Chen; Xiaoli Huang; Yao Lu; Xueyin Ni; Daoquan Fang; Dengqiang Wu; Shuangshuang Lu; Mingzhu Jiang; Chenyang Qiu; Yuya Wu; Qisha Qiu; Yanyuan Dong; Yangyang Su; Chenmin Zhao; Zhihe Zhong; Jing Cai; Yong Liang
Journal:  J Cell Mol Med       Date:  2017-04-14       Impact factor: 5.310

6.  NLRP3 Inflammasome Activation by MicroRNA-495 Promoter Methylation May Contribute to the Progression of Acute Lung Injury.

Authors:  Youguo Ying; Yong Mao; Min Yao
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-03       Impact factor: 8.886

Review 7.  Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy.

Authors:  Hairong Wang; Shiming Liu; Li Jia; Fengyun Chu; Ya Zhou; Zhixu He; Mengmeng Guo; Chao Chen; Lin Xu
Journal:  Cancer Cell Int       Date:  2018-07-13       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.